References
- FDA Press Release. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies; [accessed 2022 Jul 14]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
- Institute for Clinical and Economic Review. 2020-2023 value assessment framework; [accessed 2022 Jul 27]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_013120-4.pdf
- National Institute of Health and Care Excellence. The guidelines manual. Process and methods [PMG6]; 2012 [accessed 2022 Oct 16]. Available from: https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness
- Neumann PJ, Ollendorf DA. Why so few value assessments on health services and procedures, and what should be done?; 2022 [accessed 2023 Feb 16]. Available from: https://www.healthaffairs.org/content/forefront/why-so-few-value-assessments-health-services-and-procedures-and-should-done
- Institute for Clinical and Economic Review. Adapted value assessment methods for high-impact “single and short-term therapies” (SSTs); [accessed 2022 Jul 13]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SST_FinalAdaptations_111219.pdf
- National Institute for Health and Care Excellence. Interim process and methods of the Highly Specialised Technologies Programme updated to reflect 2017 changes; [accessed 2022 Jul 17]. Available from: https://www.nice.org.uk/media/default/about/what-we-do/nice-guidance/nice-highly-specialised-technologies-guidance/hst-interim-methods-process-guide-may-17.pdf
- Henderson N. ISPOR Issue Panel roundup: are our HTA methods fit for purpose for gene therapies?; [accessed 2022 Jul 13]. Available from: https://www.ohe.org/news/ispor-issue-panel-roundup-are-our-hta-methods-fit-purpose-gene-therapies
- Taylor C, Jan S, Thompson K. Funding therapies for rare diseases: an ethical dilemma with a potential solution. Aust Health Rev. 2018;42(1):117–119.
- Aballea S, Thokagevistk K, Velikanova R, et al. Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy. 2020;8(1):1822666.
- Williams AO, Rojanasarot S, McGovern AM, et al. A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications. J Comp Eff Res. 2023;12(2):e220167.
- Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–668.
- Jonsson B, Hampson G, Michaels J, et al. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019;20(3):427–438.
- Clay E, Pochopien M, Aballea S, et al. Differentiating discount rates in cost-effectiveness evaluations in the context of gene therapies. Value Health. 2018;21:s363.
- Chapman RH, Kumar VM, Whittington MD, et al. Does cost-effectiveness analysis overvalue potential cures? Exploring alternative methods for applying a "shared savings" approach to cost offsets. Value Health. 2021;24(6):839–845.
- Pearson SD, Ollendorf DA, Chapman RH. New cost-effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;22(6):656–660.
- Bullement A, Knowles ES, DasMahapatra P, et al. Cost-Effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia a without inhibitors in the United States. Pharmacoecon Open. 2021;5(4):625–633.
- Calamia M, McBride A, Abraham I. Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL. J Med Econ. 2021;24(sup1):14–24.
- Cao Y, Zhao L, Zhang T, et al. Cost-Effectiveness analysis of adding daratumumab to bortezomib, melphalan, and prednisone for untreated multiple myeloma. Front Pharmacol. 2021;12:608685.
- Chakraborty H, Hossain A, Latif MAHM. A three-state continuous time Markov chain model for HIV disease burden. J Applied Stat. 2019;46(9):1671–1688.
- Chen TA, Baranowski T, Moreno JP, et al. Obesity status transitions across the elementary years: use of Markov chain modelling. Pediatr Obes. 2016;11(2):88–94.
- Li N, Zheng H, Huang Y, et al. Cost-effectiveness analysis of olaparib maintenance treatment for germline BRCA-mutated metastatic pancreatic cancer. Front Pharmacol. 2021;12:632818.
- Lin S, Luo S, Gu D, et al. First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a U.S.-based cost-effectiveness analysis. Oncologist. 2021;26(11):e2013–e2020.
- Sheinson D, Dang J, Shah A, et al. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811–1831.
- Institute for Clinical and Economic Review. Cognitive and mind-body therapies for chronic low back and neck pain: effectiveness and value; 2017 Nov 6 [accessed 2022 Aug 23]. Available from: https://icer.org/wp-content/uploads/2020/10/CTAF_LBNP_Final_Evidence_Report_110617.pdf
- Novartis Press Release. AveXis announces innovative Zolgensma® gene therapy access programs for US payers and families; [accessed 2022 Jul 13]. Available from: https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families
- Harper M. Spark therapeutics sets price of blindness- treating gene therapy at $850,000; [accessed 2022 Jul 13]. Available from: https://www.forbes.com/sites/matthewherper/2018/01/03/spark-therapeutics-sets-price-of-blindness-curing-gene-therapy-at-850000/?sh=38d1e92b7dc3
- , Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234.
- Institute for Clinical and Economic Review. Siponimod for the treatment of secondary progressive multiple sclerosis: effectiveness and value; [accessed 2022 Aug 23]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_MS_Final_Evidence_Report_062019.pdf
- Potashman M, Buessing M, Levitchi Benea M, et al. Estimating progression rates across the spectrum of Alzheimer’s disease for amyloid-positive individuals using national Alzheimer’s coordinating center data. Neurol Ther. 2021;10(2):941–953.
- Arias E, Xu JQ. United States life tables, 2018. National vital statistics reports. vol. 69. Hyattsville (MD): National Center for Health Statistics; 2020.
- Armstrong EP, Malone DC, Yeh WS, et al. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822–826.
- Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1):429.
- Burke T, Asghar S, O'Hara J, et al. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US + population surveys. Orphanet J Rare Dis. 2021;16(1):143.
- Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38(6):583–637.
- Neumann PJ, Sanders GD, Russell LB, et al. editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford: Oxford University Press; 2016.
- Kansal AR, Reifsnider OS, Brand SB, et al. Economic evaluation of betibeglogene autotemcel (beti-cel) gene addition therapy in transfusion-dependent beta-thalassemia. J Mark Access Health Policy. 2021;9(1):1922028.
- Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792–1798.
- Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.
- National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy; [accessed 2022 Jul 31]. Available from: https://www.nice.org.uk/guidance/hst15/documents/committee-papers
- Institute for Clinical and Economic Review. Betibeglogene autotemcel for beta thalassemia: effectiveness and value. Final evidence report; 2022 Jul 19 [accessed 2022 Jul 28]. Available from: https://icer.org/wp-content/uploads/2021/11/ICER_Beta-Thalassemia_Final-Report_071922.pdf
- Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161–1168.
- Zorginstituut Nederland. Guideline for economic evaluations in healthcare; 2016 [accessed 2022 Jul 14]. Available from: https://english.zorginstituutnederland.nl/binaries/zinl-eng/documenten/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare/Guideline+for+economic+evaluations+in+healthcare.pdf
- Westra TA, Parouty M, Brouwer WB, et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health. 2012;15(3):562–567.
- Institute for Clinical and Economic Review. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and Value; 2020 Oct 16; [accessed 2022 Aug 20]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia-A_Evidence-Report_102620.pdf
- Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745–758.
- Postma MJ, Parouty M, Westra TA. Accumulating evidence for the case of differential discounting. Expert Rev Clin Pharmacol. 2013;6(1):1–3.
- Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–721.
- Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Management Sci. 1983;29(3):300–306.
- College voor zorgverzekeringen, Diemen. Guidelines for pharmacoeconomic research, updated version; 2006 Mar [accessed 2022 Jul 13]. Available from: https://heatinformatics.com/sites/default/files/images-videosFileContent/Netherlands%20CVZ%20Pharmacoeconomics%202006.pdf
- Brouwer WB, Niessen LW, Postma MJ, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J. 2005;331(7514):446–448.
- John J, Koerber F, Schad M. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc. 2019;17:29.
- Nord E. Discounting future health benefits: the poverty of consistency arguments. Health Econ. 2011;20(1):16–26.
- Paulden M, O'Mahony JF, McCabe C. Discounting the recommendations of the second panel on cost-effectiveness in health and medicine. Pharmacoeconomics. 2017;35(1):5–13.
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices–budget impact analysis. Value Health. 2007;10(5):336–347.
- Institute for Clinical and Economic Review. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value. Final evidence report; [accessed 2023 Mar 8]. Available from: https://icer.org/wp-content/uploads/2022/05/ICER_Hemophilia_Final_Report_12222022.pdf
- Drummond M, Brixner D, Gold M, et al. Toward a consensus on the QALY. Value Health. 2009;12 Suppl 1:s31–s35.
- Jamison DT, Breman JG, Measham AR, et al., editors. Priorities in health. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2006. Chapter 3, Cost-effectiveness analysis; [accessed 2022 Aug 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10253/
- MEPACT® (mifamurtide) Prescribing Information; [accessed 2022 Aug 1]. Available from: https://www.takeda.com/siteassets/system/hcps/mepact-prescribing-information.pdf
- National Institute for Health and Care Excellence; [accessed 2022 Jul 13]. Available from: https://www.nice.org.uk/guidance/ta235/resources/mifamurtide-for-the-treatment-of-osteosarcoma-pdf-82600372273093
- Ralston S, Floyd D, Ratcliffe M. Differential discouting: capturing the value of living longer and better. Value Health. 2013;16(7):A467.
- Monnette A, Chen E, Hong D, et al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36.
- van Overbeeke E, Hauber B, Michelsen S, et al. Patient preferences for gene therapy in haemophilia: results from the PAVING threshold technique survey. Haemophilia. 2021;27(6):957–966.
- Witkop M, Morgan G, O'Hara J, et al. Patient preferences and priorities for haemophilia gene therapy in the US: a discrete choice experiment. Haemophilia. 2021;27(5):769–782.
- Institute for Clinical and Economic Review. Spinraza® and Zolgensma® for spinal muscular atrophy: effectiveness and value; [accessed 2021 Jul 13]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SMA_Final_Evidence_Report_110220.pdf
- Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics. 2008;26(7):589–602.
- Cubanski J, Neuman T. Prices increased faster than inflation for half of all drugs covered by Medicare in 2020; [accessed 2022 Jul 13]. Available from: https://www.kff.org/medicare/issue-brief/prices-increased-faster-than-inflation-for-half-of-all-drugs-covered-by-medicare-in-2020/
- Schmickel B, Perry K, Sanchez H, et al. Exploring the truth of reimbursement challenges for cell and gene therapies; [accessed 2022 Aug 1]. Available from: https://trinitylifesciences.com/wp-content/uploads/2021/05/Trinity_Reimbursement_Challenges-6.10.19-1.pdf
- Lakdawalla DN, Doshi JA, Garrison LP, Jr., et al. Defining elements of value in health Care-A health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–139.
- Leroy BP, Fischer MD, Flannery JG, et al. Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Res. 2023;66:179–196.
- Mendell JR, Wigderson M, Alecu I, et al. Long-term follow-up of onasemnogene abeparvovec gene therapy in symptomatic patients with spinal muscular atrophy type 1. Abstract presented at the 2023 MDA Clinical & Scientific Conference, Dallas, TX; 2023 Mar 19–22.
- Institute for Clinical and Economic Review. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma final report; [accessed 2022 Jul 13]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Update_070921.pdf
- Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941.